Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

PCVX

Phase 3

VAX-24

Invasive PneumococcaI Disease (IPD) in Adults

H2 2025

1/5/24 Successful End-of-Phase 2 meeting. To initiate Ph3 study in H2 2024 w/ top-line data in H2 2025.

Data readout

LYEL

Phase 1

LYL119

Solid tumors (ROR+)

H2 2025

IND submission in Q2 '24. Accepts IND & initial data in H2 2025.

Data readout

TNGX

Phase 1/2

TNG462 ( PRMT5 inhibitor)

Solid tumors

2025

Q1 '24 Initiate Dose expansion in Q2 '24. 11/6/24 Positive Ph1/2 data. Next clinical update is in 2025 from higher doses. Combination studies in H1 '25.

Data readout

ALKS

Phase 2

ALKS 2680 (RDC-264177) ( Orexin 2 Receptor Agonist)

Narcolepsy type 1 (NT1)

H2 2025

Vibrance-1 (NT1). 4/9/24- Positive Ph1b data. 7/24/24- Ph2 trial initiated. Q3'24- Ongoing Ph2 with prior positive Ph1b data presented in Oct 2024. Complete ongoing Ph2 study in 2025, with potential for registrational studies preparation. 2/12/25- Topline data in H2 2025.

Data readout

BLRX

Phase 1

Motixafortide (BL-8040)

Sickle cell disease gene therapy (CD34+ HSCs) (aged 18 and older)

2025

Agreement w/St. Jude Children's Research Hospital: 8/15/24 First patient dosed in Sep 2024 & Initial data in 2025.

Data Readout

PYXS

Phase 1

PYX-201

Breast, Head & Neck, Lung and Thyroid Cancer

2025

PYX-201-101 trial. Second dose level initiated in the Ph1 trial. Enrolling 7th cohort. 11/20/24- Reported preliminary Ph1 data. Multiple data updates in 2025. 2/26/25- Granted Fast Track Designation.

Data readout

BDTX

Phase 2

BDTX-1535

Non-small cell lung cancer (NSCLC) (2L/3L), Recurrent EGFRm NSCLC

H2 2025

2L/3L NSCLC (Recurrent EGFRm NSCLC). 9/11/23- 1st patient dosed in expansion cohorts. 4/7/24 Real-world data at AACR '24. 9/23/24- Positive initial Ph2 data. 3/6/25- Phase 2 trial updated data in H2 2025.

Data readout

ELVN

Phase 1a

ELVN-002 w/ trastuzumab +/- chemotherapeutic agents

Metastatic breast cancer (MBC) & colorectal cancer (CRC)

2025

8/13/24 Dosed first patient in the Ph1a combination therapy. Initial data in 2025.

Data readout

ALVO

PDUFA

AVT05 (Proposed Biosimilar to Simponi® & Simponi Aria® (golimumab))

Inflammatory conditions

Q4 2025

Collab w/ Teva. 1/27/25- FDA accepted for review of BLA. The FDA review process for these applications is anticipated to be completed in the Q4 2025.

Approval decision

CLDX

Phase 2

Barzolvolimab (CDX-0159) (KIT receptor)

Atopic Dermatitis

2025

12/19/24- Initiated Ph2 study with multiple upcoming data readouts in 2025.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20